Sogroya fda approval?

What did the FDA approve for Sogroya?

Sogroya (somapacitan-becoate) is an injectable growth hormone (GH) treatment. The FDA approved it for patients who need treatment for growth failure due to inadequate secretion of endogenous GH. The approval covers use in appropriate pediatric and adult groups as specified in the FDA’s prescribing information. [1]

When was Sogroya approved by the FDA?

The FDA approval date for Sogroya is May 10, 2023. [1]

Who is Sogroya for (and what conditions does it treat)?

FDA approval is for growth failure due to inadequate secretion of endogenous GH, including pediatric patients and adults who meet the criteria outlined in the labeling. [1]

What is the dosing schedule after FDA approval?

Sogroya is given as a once-weekly subcutaneous injection, as reflected in the FDA-approved prescribing information. [1]

How is Sogroya different from older growth hormone injections?

Sogroya is designed as a once-weekly option (instead of daily GH regimens). FDA labeling positions it as a long-acting therapy intended to match a weekly injection schedule. [1]

What side effects do patients ask about after FDA approval?

Common adverse reactions listed in the FDA-approved labeling include injection-site reactions and effects related to GH/insulin-like growth factor signaling; the full list is in the prescribing information. [1]

Sources

1. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214545